CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.
Gout Resource Center
Earlier this year, the ACR released a new guideline for the management of gout, leaving some rheumatologists unsure what to recommend to their patients. Clearing up the confusion is one aim of the session, Evidence-Based Guidance for Optimizing Gout Management. Learn what the experts recommend and explore our coverage of additional gout information presented at ACR Convergence 2020, plus our collection of research reviews, case reports and clinical articles on advances in the diagnosis and management of gout.
VIEW
Let’s Discuss Part 2: More Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on cutaneous manifestations of rheumatic diseases, gout, macrophage activation syndrome and vasculitis.
Gout & Cardiometabolic Co-Morbidities
ACR Convergence 2025 experts explore gout’s deep ties to MetS, insulin resistance and cardiovascular mortality, weighing new data on colchicine, febuxostat and SGLT2 inhibitors.
Promising Combination Treatment for Gout
The FDA has accepted a biologics license application for nano-encapsulated sirolimus with pegylated-adricase (NASP), a combination treatment designed to reduce serum uric acid levels in patients with uncontrolled gout.
Calcium Pyrophosphate Deposition Disease: The Great Mimic
CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.
Gout Flares & the NLRP3 Inflammasome
Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as a new treatment option.
SAP-001 Promising for Refractory Gout
Initial findings from a phase 2b clinical trial demonstrate the safety and efficacy of three different daily doses of SAP-001 to lower the serum urate levels of patients with refractory gout.
FDA Approves Oral Solution of Colchicine to Prevent Gout Flare
The FDA approved an oral solution of colchicine for the prevention of gout flare in adults. Its dosage can be easily adjusted on the basis of patient needs.
A ‘Polarized’ Topic: Synovial Fluid Crystal Examinations
Answer a short survey to help the ACR’s Committee on Rheumatologic Care decide whether the ACR should seek CMS approval for synovial fluid crystal analysis as a provider-performed microscopy procedure.
Sunrise, Sunset: A Look Back on the Year in Rheumatology
At the ACR Convergence 2024 Year in Review lecture, experts discussed advancements in disease understanding and treatments, as well as in basic science.
- 1
- 2
- 3
- …
- 22
- Next Page »